Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma
- Author(s)
- Zwimpfer, TA; Ewald, H; Bilir, E; Jayawardana, M; Appenzeller-Herzog, C; Bizzarri, N; Razumova, Z; Kacperczyk-Bartnik, J; Heinzelmann-Schwarz, V; Friedlander, M; Bowtell, DDL; Garsed, DW;
- Journal Title
- Cochrane Database of Systematic Reviews
- Publication Type
- Protocol
- Abstract
- This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.
- Publisher
- Cochrane Library
- Keywords
- Humans; *Ovarian Neoplasms/genetics/mortality; Female; Fallopian Tube Neoplasms/genetics/mortality/pathology/drug therapy; Cystadenocarcinoma, Serous/genetics/mortality; Prognosis; Progression-Free Survival; Genes, BRCA2; Genes, BRCA1; Mutation
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1002/14651858.Cd015896
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-01 07:31:05
Last Modified: 2024-10-01 07:37:32